Type 1 innate lymphoid cells are associated with type 2 diabetes - 15/08/19
, Y. Bi b
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Aim |
Type 1 innate lymphoid cells (ILC1s) play a major role in regulating systemic inflammatory diseases. However, the relationship between ILC1s and type 2 diabetes (T2D) remains unclear. Thus, the present study investigated the relationship between ILC1s and glucose homoeostasis in humans.
Methods |
A total of 37 newly diagnosed T2D patients and 32 subjects with normal glucose tolerance (NGT), matched for age and body mass index (BMI), were enrolled in the study. Flow cytometric analysis of ILC1s derived from peripheral blood mononuclear cells (PBMCs) and omental adipose tissue was performed.
Results |
T2D patients displayed greater numbers and frequencies of circulating and adipose tissue ILC1s (P < 0.05) compared with NGT subjects, and the two types of ILC1s correlated positively with each other. Circulating ILC1s were positively associated with glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), homoeostasis model assessment for insulin resistance (HOMA-IR), adipose tissue insulin resistance index (Adipo-IR) and serum free fatty acids (FFAs). A logistic regression model revealed that patients with higher ILC1 levels exhibited a 13.481-fold greater risk of developing T2D.
Conclusion |
This study is the first to provide evidence that ILC1 abnormalities are involved in the development of diabetes. The data also suggest a potential role of ILC1s as therapeutic indicators in the treatment of T2D.
Le texte complet de cet article est disponible en PDF.Abbreviations : ILC1s, T2D, NGT, BMI, PBMCs, SVF, HbA1c, FPG, HOMA-IR, Adipo-IR, FFA, OGTT, WHR, ALT, AST, GGT, eGFR, CKD-Epi, CBC, TGs, TC, HDL-C, LDL-C, HOMA-β, CPTs, PBS, FBS, RBC, HFD, WT, OR, CI, NK, Eomes
Keywords : Adipose inflammation, Glycaemic disturbance, Insulin resistance, Type 1 innate lymphoid cell, Type 2 diabetes
Plan
Vol 45 - N° 4
P. 341-346 - septembre 2019 Retour au numéro
Article précédent
- Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200?U/mL) and insulin glargine (100, 300?U/mL)?–?a review of evidence and clinical interpretation
- D.R. Owens, T. S Bailey, C.G. Fanelli, J.-F. Yale, G.B. Bolli
- Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes
- A. Mantovani, E. Sani, A. Fassio, A. Colecchia, O. Viapiana, D. Gatti, L. Idolazzi, M. Rossini, G. Salvagno, G. Lippi, G. Zoppini, C.D. Byrne, E. Bonora, Giovanni Targher
Bienvenue sur EM-consulte, la référence des professionnels de santé.